1887

Abstract

Chimeric foot-and-mouth disease viruses (FMDV) of which the antigenic properties can be readily manipulated is a potentially powerful approach in the control of foot-and-mouth disease (FMD) in sub-Saharan Africa. FMD vaccine application is complicated by the extensive variability of the South African Territories (SAT) type viruses, which exist as distinct genetic and antigenic variants in different geographical regions. A cross-serotype chimeric virus, vKNP/SAT2, was engineered by replacing the external capsid-encoding region (1B-1D/2A) of an infectious cDNA clone of the SAT2 vaccine strain, ZIM/7/83, with that of SAT1 virus KNP/196/91. The vKNP/SAT2 virus exhibited comparable infection kinetics, virion stability and antigenic profiles to the KNP/196/91 parental virus, thus indicating that the functions provided by the capsid can be readily exchanged between serotypes. As these qualities are necessary for vaccine manufacturing, high titres of stable chimeric virus were obtained. Chemically inactivated vaccines, formulated as double-oil-in-water emulsions, were produced from intact 146S virion particles of both the chimeric and parental viruses. Inoculation of guinea pigs with the respective vaccines induced similar antibody responses. In order to show compliance with commercial vaccine requirements, the vaccines were evaluated in a full potency test. Pigs vaccinated with the chimeric vaccine produced neutralizing antibodies and showed protection against homologous FMDV challenge, albeit not to the same extent as for the vaccine prepared from the parental virus. These results provide support that chimeric vaccines containing the external capsid of field isolates can be successfully produced and that they induce protective immune responses in FMD host species.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.027151-0
2011-04-01
2019-11-13
Loading full text...

Full text loading...

/deliver/fulltext/jgv/92/4/849.html?itemId=/content/journal/jgv/10.1099/vir.0.027151-0&mimeType=html&fmt=ahah

References

  1. Amadori, M., Berneri, C. & Archetti, I. L. ( 1994; ). Immunogenicity of foot-and-mouth disease virus grown in BHK-21 suspension cells. Correlation with cell ploidy alterations and abnormal expression of the α5β1 integrin. Vaccine 12, 159–166. [CrossRef]
    [Google Scholar]
  2. Anderson, E. C., Masters, R. C. & Mowat, G. N. ( 1971; ). Immune response of pigs to inactivated foot-and-mouth disease vaccines. Response to emulsion vaccines. Res Vet Sci 12, 342–350.
    [Google Scholar]
  3. Baranowski, E., Sevilla, N., Verdaguer, N., Ruiz-Jarabo, C. M., Beck, E. & Domingo, E. ( 1998; ). Multiple virulence determinants of foot-and-mouth disease virus in cell culture. J Virol 72, 6362–6372.
    [Google Scholar]
  4. Barnett, P. V. & Carabin, H. ( 2002; ). A review of emergency foot-and-mouth disease (FMD) vaccines. Vaccine 20, 1505–1514. [CrossRef]
    [Google Scholar]
  5. Barnett, P. V., Pullen, L., Staple, R. F., Lee, L. J., Butcher, R., Parkinson, D. & Doel, T. R. ( 1996; ). A protective anti-peptide antibody against the immunodominant site of the A24 Cruzeiro strain of foot-and-mouth disease virus and its reactivity with other subtype viruses containing the same minimum binding sequence. J Gen Virol 77, 1011–1018. [CrossRef]
    [Google Scholar]
  6. Barnett, P. V., Statham, R. J., Vosloo, W. & Haydon, D. T. ( 2003; ). Foot-and-mouth disease vaccine potency testing: determination and statistical validation of a model using a serological approach. Vaccine 21, 3240–3248. [CrossRef]
    [Google Scholar]
  7. Bastos, A. D. S., Haydon, D. T., Forsberg, R., Knowles, N. J., Anderson, E. C., Bengis, R. G., Nel, L. H. & Thomson, G. R. ( 2001; ). Genetic heterogeneity of SAT-1 type foot-and-mouth disease viruses in southern Africa. Arch Virol 146, 1537–1551. [CrossRef]
    [Google Scholar]
  8. Bastos, A. D. S., Haydon, D. T., Sangaré, O., Boshoff, C. I., Edrich, J. L. & Thomson, G. R. ( 2003; ). The implications of virus diversity within the SAT 2 serotype for control of foot-and-mouth disease in sub-Saharan Africa. J Gen Virol 84, 1595–1606. [CrossRef]
    [Google Scholar]
  9. Beard, C., Ward, G., Rieder, E., Chinsangaram, J., Grubman, M. J. & Mason, P. W. ( 1999; ). Development of DNA vaccines for foot-and-mouth disease, evaluation of vaccines encoding replicating and non-replicating nucleic acids in swine. J Biotechnol 73, 243–249. [CrossRef]
    [Google Scholar]
  10. Brehm, K. E., Kumar, N., Thulke, H. H. & Haas, B. ( 2008; ). High potency vaccines induce protection against heterologous challenge with foot-and-mouth disease virus. Vaccine 26, 1681–1687. [CrossRef]
    [Google Scholar]
  11. Burman, A., Clark, S., Abrescia, N. G. A., Fry, E. E., Stuart, D. I. & Jackson, T. ( 2006; ). Specificity of the VP1 GH loop of foot-and-mouth disease virus for αv integrins. J Virol 80, 9798–9810. [CrossRef]
    [Google Scholar]
  12. Cloete, M., Dungu, B., Van Staden, L. I., Ismail-Cassim, N. & Vosloo, W. ( 2008; ). Evaluation of different adjuvants for foot-and-mouth disease vaccine containing all the SAT serotypes. Onderstepoort J Vet Res 75, 17–31.
    [Google Scholar]
  13. DiCara, D., Burman, A., Clark, S., Berryman, S., Howard, M. J., Hart, I. R., Marshall, J. F. & Jackson, T. ( 2008; ). Foot-and-mouth disease virus forms a highly stable, EDTA-resistant complex with its principal receptor, integrin αvβ6: implications for infectiousness. J Virol 82, 1537–1546. [CrossRef]
    [Google Scholar]
  14. Doel, T. R. ( 1996; ). Natural and vaccine-induced immunity to foot and mouth disease: the prospects for improved vaccines. Rev Sci Tech 15, 883–911.
    [Google Scholar]
  15. Doel, T. R. ( 2003; ). FMD vaccines. Virus Res 91, 81–99. [CrossRef]
    [Google Scholar]
  16. Doel, T. R. & Baccarini, P. J. ( 1981; ). Thermal stability of foot-and-mouth disease virus. Arch Virol 70, 21–32. [CrossRef]
    [Google Scholar]
  17. Doel, T. R. & Collen, T. ( 1983; ). The detection and inhibition of proteolytic enzyme activity in concentrated preparations of inactivated foot-and-mouth disease virus. J Biol Stand 11, 35–46. [CrossRef]
    [Google Scholar]
  18. Doel, T. R. & Mowat, G. N. ( 1985; ). An international collaborative study on foot and mouth disease virus assay methods. 2. Quantification of 146S particles. J Biol Stand 13, 335–344. [CrossRef]
    [Google Scholar]
  19. Esterhuysen, J. J. ( 1994; ). The antigenic variation of foot-and-mouth disease viruses and its significance in the epidemiology of the disease in Southern Africa. MSc thesis, University of Pretoria, South Africa.
  20. Esterhuysen, J. J., Thomson, G. R., Ashford, W. A., Lentz, D. W., Gainaru, M. D., Sayer, A. J., Meredith, C. D., Janse van Rensburg, D. & Pini, A. ( 1988; ). The suitability of a rolled BHK21 monolayer system for the production of vaccines against the SAT types of foot-and-mouth disease virus. I. Adaptation of virus isolates to the system, immunogen yields achieved and assessment of subtype cross reactivity. Onderstepoort J Vet Res 55, 77–84.
    [Google Scholar]
  21. European Pharmacopoeia ( 2006; ). Foot-and-mouth disease (ruminants) vaccine (inactivated) 04/2005:0063, 5th edn, version 5.5.
  22. Fox, G., Parry, N. R., Barnett, P. V., McGinn, B., Rowlands, D. J. & Brown, F. ( 1989; ). The cell attachment site on foot-and-mouth disease virus includes the amino acid sequence RGD (arginine-glycine-aspartic acid). J Gen Virol 70, 625–637. [CrossRef]
    [Google Scholar]
  23. Fry, E. E., Lea, S. M., Jackson, T., Newman, J. W. I., Ellard, F. M., Blakemore, W. E., Abu-Ghazaleh, R., Samuel, A., King, A. M. Q. & Stuart, D. I. ( 1999; ). The structure and function of a foot-and-mouth disease virus-oligosaccharide receptor complex. EMBO J 18, 543–554. [CrossRef]
    [Google Scholar]
  24. Hunter, P. ( 1996; ). The performance of southern African territories serotypes of foot and mouth disease antigen in oil-adjuvanted vaccines. Rev Sci Tech 15, 913–922.
    [Google Scholar]
  25. Jackson, T., Ellard, F. M., Ghazaleh, R. A., Brookes, S. M., Blakemore, W. E., Corteyn, A. H., Stuart, D. I., Newman, J. W. I. & King, A. M. Q. ( 1996; ). Efficient infection of cells in culture by type O foot-and-mouth disease virus requires binding to cell surface heparan sulfate. J Virol 70, 5282–5287.
    [Google Scholar]
  26. Jackson, T., King, A. M. Q., Stuart, D. I. & Fry, E. ( 2003; ). Structure and receptor binding. Virus Res 91, 33–46. [CrossRef]
    [Google Scholar]
  27. Kärber, G. ( 1931; ). Beitrag zur kollektiven behandlung pharmakologischer Rreihenversuche. Naunyn Schmiedebergs Arch Pharmacol 162, 480–483 (in German ). [CrossRef]
    [Google Scholar]
  28. King, A. M. Q. ( 2000; ). Picornaviridae. In Virus Taxonomy (Seventh Report of the International Committee for the Taxonomy of Viruses), pp. 657–673. Edited by Van Regenmortel, M. H. V.. New York. : Academic Press.
    [Google Scholar]
  29. Knipe, T., Rieder, E., Baxt, B., Ward, G. & Mason, P. W. ( 1997; ). Characterization of synthetic foot-and-mouth disease virus provirions separates acid-mediated disassembly from infectivity. J Virol 71, 2851–2856.
    [Google Scholar]
  30. Reeve, R., Blignaut, B., Esterhuysen, J. J., Opperman, P., Matthews, L., Fry, E. E., de Beer, T. A. P., Theron, J., Rieder, E. & other authors ( 2010; ). Sequence-based prediction for vaccine strain selection and identification of antigenic variability in foot-and-mouth disease virus. PLoS Comput Biol 6, e1001027.[CrossRef]
    [Google Scholar]
  31. Maree, F. F., Blignaut, B., de Beer, T. A., Visser, N. & Rieder, E. A. ( 2010; ). Mapping of amino acid residues responsible for adhesion of cell culture-adapted foot-and-mouth disease SAT type viruses. Virus Res 153, 82–91. [CrossRef]
    [Google Scholar]
  32. Mason, P. W., Rieder, E. & Baxt, B. ( 1994; ). RGD sequence of foot-and-mouth disease virus is essential for infecting cells via the natural receptor but can be bypassed by an antibody-dependent enhancement pathway. Proc Natl Acad Sci U S A 91, 1932–1936. [CrossRef]
    [Google Scholar]
  33. McCullough, K. C., De Simone, F., Brocchi, E., Capucci, L., Crowther, J. R. & Kihm, U. ( 1992; ). Protective immune response against foot-and-mouth disease. J Virol 66, 1835–1840.
    [Google Scholar]
  34. Office International des Epizooties ( 2009; ). Manual of Diagnostic Tests and Vaccines for Terrestrial Animals 2009, Chapter 2.1.5, pp. 1–25. Paris, France. : Office International des Epizooties.
    [Google Scholar]
  35. Pay, T. W. F. ( 1983; ). Variation in foot and mouth disease: application to vaccination. Rev sci tech Off int Epiz 2, 701–723.
    [Google Scholar]
  36. Rieder, E., Bunch, T., Brown, F. & Mason, P. W. ( 1993; ). Genetically engineered foot-and-mouth disease viruses with poly(C) tracts of two nucleotides are virulent in mice. J Virol 67, 5139–5145.
    [Google Scholar]
  37. Rieder, E., Baxt, B., Lubroth, J. & Mason, P. W. ( 1994; ). Vaccines prepared from chimeras of foot-and-mouth disease virus (FMDV) induce neutralizing antibodies and protective immunity to multiple serotypes of FMDV. J Virol 68, 7092–7098.
    [Google Scholar]
  38. Rweyemamu, M. M. ( 1978; ). The selection of vaccine strains of foot and mouth disease virus. Br Vet J 134, 63–67.
    [Google Scholar]
  39. Sa-Carvalho, D., Rieder, E., Baxt, B., Rodarte, R., Tanuri, A. & Mason, P. W. ( 1997; ). Tissue culture adaptation of foot-and-mouth disease virus selects viruses that bind to heparin and are attenuated in cattle. J Virol 71, 5115–5123.
    [Google Scholar]
  40. Sevilla, N., Verdaguer, N. & Domingo, E. ( 1996; ). Antigenically profound amino acid substitutions occur during large population passages of foot-and-mouth disease virus. Virology 225, 400–405. [CrossRef]
    [Google Scholar]
  41. Storey, P., Theron, J., Maree, F. F. & O'Neill, H. G. ( 2007; ). A second RGD motif in the 1D capsid protein of a SAT1 type foot-and-mouth disease virus field isolate is not essential for attachment to target cells. Virus Res 124, 184–192. [CrossRef]
    [Google Scholar]
  42. van Rensburg, H. G., Henry, T. M. & Mason, P. W. ( 2004; ). Studies of genetically defined chimeras of a European type A virus and a South African Territories type 2 virus reveal growth determinants for foot-and-mouth disease virus. J Gen Virol 85, 61–68. [CrossRef]
    [Google Scholar]
  43. Vianna Filho, Y. L., Astudillo, V., Gomes, I., Fernández, G., Rozas, C. E. E., Ravison, J. A. & Alonso, A. ( 1993; ). Potency control of foot-and-mouth disease vaccine in cattle. Comparison of the 50% protective dose and the protection against generalization. Vaccine 11, 1424–1428. [CrossRef]
    [Google Scholar]
  44. Vosloo, W., Kirkbride, E., Bengis, R. G., Keet, D. F. & Thomson, G. R. ( 1995; ). Genome variation in the SAT types of foot-and-mouth disease viruses prevalent in buffalo (Syncerus caffer) in the Kruger National Park and other regions of southern Africa, 1986-93. Epidemiol Infect 114, 203–218. [CrossRef]
    [Google Scholar]
  45. Ward, M. P., Laffan, S. W. & Highfield, L. D. ( 2007; ). The potential role of wild and feral animals as reservoirs of foot-and-mouth disease. Prev Vet Med 80, 9–23. [CrossRef]
    [Google Scholar]
  46. Zibert, A., Maass, G., Strebel, K., Falk, M. M. & Beck, E. ( 1990; ). Infectious foot-and-mouth disease virus derived from a cloned full-length cDNA. J Virol 64, 2467–2473.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.027151-0
Loading
/content/journal/jgv/10.1099/vir.0.027151-0
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error